Monte Rosa Therapeutics is a biotechnology company that develops cancer therapeutics that modulate protein degradation pathways.
Monte Rosa has raised €80M across 1 funding round from 1 investor, most recently a Series C round in Mar 2021. Based in Basel, Switzerland; founded 2018; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2021-03-24 | Series C |
| €80M |
| Avoro Capital Advisors |
| View deal → |
